TheranosticTrials.org

Clinical Trial · NCT06675357

Using FAPI PET/MRI to Evaluate Prostate Cancer

Overview

The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue. The main question it aims to answer is how this information can be used to better diagnose and track prostate cancer. Participants will undergo two PET/MRI scans during two research visits, each of which may last up to 2.5 hours.

Sponsor

University of Wisconsin, Madison

Phase

Phase 2

Contacts

Ali Pirasteh, MD (PRINCIPAL_INVESTIGATOR)

Radiology Studies (CONTACT)

radstudy@uwhealth.org

608-282-8349

ClinicalTrials.gov

NCT06675357

Drug / Compound

FAPI

Isotope(s):
Target(s):
  • FAP
Ligand Class: Small Molecules
Chelator: DOTA

Eligibility

Inclusion

  • Optional: Scheduled for SOC biopsy of an established or suspected non-osseous, non-nodal metastases.
  • * Age 18 years or older
  • Known diagnosis of prostate cancer
  • Scheduled for or recently performed (within 4 weeks) standard-of-care PSMA PET
  • Able and willing to provide informed consent

Exclusion

  • * Unable or unwilling to provide informed consent
  • Participants requiring intravenous (IV) conscious sedation for imaging care; those requiring mild, oral anxiolytics for the clinical MRI will be allowed to participate as long as the following criteria are met:
  • Participants for whom PET/MRI will delay timely delivery of treatment
  • Contraindication(s) to or inability to undergo PET/MRI
  • Have their own prescription for the medication